{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["61(6)"],"submitter":["Violet J"],"pubmed_abstract":["<sup>177</sup>Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen (PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported favorable activity with low toxicity in a prospective phase II trial involving 30 men with metastatic castration-resistant prostate cancer. We now report their longer-term outcomes, including a 20-patient extension cohort and outcomes of subsequent systemic treatments after completion of trial therapy. <b>Methods:</b> Fifty patients with PSMA-avid metastatic castration-resistant prostate cancer who had progressed after standard therapies received up to 4 cycles of <sup>177</sup>Lu-PSMA every 6 wk. Endpoints included prostate-specific antigen (PSA) response (Prostate Cancer Working Group 2), toxicity (Com"],"journal":["Journal of nuclear medicine : official publication, Society of Nuclear Medicine"],"pagination":["857-865"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7262220"],"repository":["biostudies-literature"],"pubmed_title":["Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer."],"pmcid":["PMC7262220"],"pubmed_authors":["Sandhu S","Kumar AR","Jackson P","Eu P","Hicks RJ","Tran B","Scalzo M","Ferdinandus J","Hofman MS","Kong G","Iravani A","Pattison DA","Mooi J","Violet J","Kalff V","Thang SP","Akhurst T","Beaulieu A","Murphy DG","Guo C","Williams S"],"additional_accession":[]},"is_claimable":false,"name":"Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.","description":"<sup>177</sup>Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen (PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported favorable activity with low toxicity in a prospective phase II trial involving 30 men with metastatic castration-resistant prostate cancer. We now report their longer-term outcomes, including a 20-patient extension cohort and outcomes of subsequent systemic treatments after completion of trial therapy. <b>Methods:</b> Fifty patients with PSMA-avid metastatic castration-resistant prostate cancer who had progressed after standard therapies received up to 4 cycles of <sup>177</sup>Lu-PSMA every 6 wk. Endpoints included prostate-specific antigen (PSA) response (Prostate Cancer Working Group 2), toxicity (Com","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jun","modification":"2026-04-30T08:19:13.555Z","creation":"2021-02-21T01:07:51Z"},"accession":"S-EPMC7262220","cross_references":{"pubmed":["31732676"],"doi":["10.2967/jnumed.119.236414"]}}